Home Aradigm Co. (ARDM) Downgraded to "Sell" at Zacks Investment Research
 

Keywords :   


Aradigm Co. (ARDM) Downgraded to "Sell" at Zacks Investment Research

2016-03-24 14:49:09| Biotech - Topix.net

According to Zacks, "Aradigm Corp. is a leading developer of advanced pulmonary drug delivery systems for the treatment of systemic conditions as well as lung diseases. Their hand-held AERx platform is being designed for the rapid and reproducible delivery of a wide range of pharmaceutical drugs and biotech compounds via the lung.

Tags: research sell investment downgraded

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
25.11Dr.
25.112BOX
25.11 Bianchi roma4
25.11PS3 CECH-2000A HDD1TB
25.11
25.11
25.11SUN FRAME B2 51.5×72.8cm
25.11 Jack Bunny
More »